Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298971 | 0.88 | CYP2D6 (0.49) | GPR119STS | |
| SCHEMBL1875061 | 0.87 | GPR119 (0.56) | GPR119STSTGFBR1 | |
| SCHEMBL3413595 | 0.84 | NAMPT (0.43) | RORCGPR119USP30STSNAMPT | |
| SCHEMBL3413600 | 0.81 | STS (0.56) | RORCGPR119USP30STSNAMPT | |
| SCHEMBL11300131 | 0.80 | MCL1 (0.46) | NR1H2NR1H3 | |
| SCHEMBL28557409 | 0.80 | NAMPT (0.49) | RORCGPR119STSNAMPTTGFBR1 | |
| SCHEMBL28557411 | 0.80 | RORC (0.43) | RORCGPR119USP30STSNAMPT | |
| SCHEMBL26961007 | 0.80 | RORC (0.47) | RORCGPR119USP30STSNAMPT | |
| SCHEMBL25235454 | 0.79 | CYP2D6 (0.44) | GPR119STS | |
| SCHEMBL221064 | 0.79 | CYP2D6 (0.54) | GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | RORC 1564/4885GPR119 1203/4885USP30 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.